BioCardia, Inc. (BCDA) intrinsic value & 10-year financials
BioCardia, Inc. (BCDA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 24.9% a year to $0, with an average return on invested capital of 494.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.92
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- -24.9%
- ROIC (10-yr avg)
- 494.8%
- Free cash flow (FY2025)
- -$7.4M
BCDA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$8.2M | — | -$7.4M | — | 666.8% |
| FY2024 | $58.0K | -$7.9M | — | -$8.0M | -13794.8% | 594.4% |
| FY2023 | $477.0K | -$11.6M | — | -$10.0M | -2441.1% | 808.9% |
| FY2022 | $1.4M | -$11.9M | — | -$10.6M | -880.3% | 1177.7% |
| FY2021 | $1.0M | -$12.6M | — | -$10.5M | -1244.3% | 815.6% |
| FY2020 | $145.0K | -$15.0M | — | -$12.4M | -10709.7% | 642.8% |
| FY2019 | $710.0K | -$14.7M | — | -$9.6M | -2001.8% | 546.4% |
| FY2018 | $625.0K | -$14.0M | — | -$11.1M | -2256.3% | -189.1% |
| FY2017 | $479.0K | -$12.3M | — | -$8.8M | -2589.8% | -78.2% |
| FY2016 | $576.0K | -$10.3M | — | — | -1320.8% | -37.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BioCardia, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BioCardia, Inc. has historically struggled to out-earn its cost of capital, averaging just -6.5% ROIC.
BioCardia, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BioCardia, Inc. is modeled at -24.9% normalized earnings growth with a 5.1% bond-yield adjustment.